Peringkat dalam Saham
#2843
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops... CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Kapitalisasi Pasar
$6.96B
Perubahan (1 tahun)
210.23%
Perdagangan CG Oncology Inc. (CGON)
Jumlah saham beredar untuk CG Oncology Inc. (CGON)
Jumlah saham beredar per August 2026: 0
Menurut laporan keuangan terbaru dan harga saham CG Oncology Inc., jumlah saham beredar saat ini adalah 0. Pada akhir August 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk CG Oncology Inc. (CGON) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun |
Saham Beredar |
Mengubah |
|
Tidak cukup data untuk tanggal yang disediakan. |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan |
Saham Beredar |
Perbedaan |
Negara |
|
|
253.90M |
-
|
US
|
|
|
62.19M |
-
|
NL
|
|
|
396.00M |
-
|
US
|
|
|
478.91M |
-
|
AU
|
|
|
- |
-
|
CH
|